The improvement effect of simvastatin on the plasma fibrinolysis activities in patients with coronary heart disease (CHD)

LIU Yong-ping,ZHENG Xing,QIN Yong-wen
2006-01-01
Abstract:Objective To investigate the effect of simvastatin,ticlopidin and aspirin on the plasma plasminogen activitor inhibitor-l(PAI-1) contents in CHD patients.Method Seventy-two CHD patients(m 34,f 31,50-75 years old) who were diagnosed by coronary angiography in Changhai hospital from March. 2003 to Oct. 2003 were divided into 2 group:A and B.The group A (33 patients) was given ticlopidin 250mg bid, aspirin 300mg qd, simvastatin 20mg qn,and the group B included 32 patients was given ticlopidin 250mg bid,aspirin 300mg qd for four weeks, The plasma PAI-1,t-PA and CRP were measured before and after the treatment-Results The plasma content of PAI-1(37.69±17 vs 26.79±13.34ng/ml,P< 0.01), t-PA (12.92±10.53 vs 8.72±6.98ng/ml,P<0.05), and CRP(13.90±20.03 vs 6.50±5.60mg/L,P< 0.05) were decreased significantly in group A. The plasma content of PAI-1 (37.65±17.18 vs 33.42± 12.30ng/ml,P<0.05), and CRP (13.98±13.22 vs 10.25±6.08mg/L,P<0.05) were also decreased in group B.The content of CRP(A:6.50±5.60 vs B:10.25±6.08mg/L,P<0.05)and PAI-1(A:26.79±13.34 vs B:33.42± 12.30ng/ml,P<0.05)decreased more significantly in group A than that in group B.Conclusion Antiplatlete therapy can improve the fibrinolitic activity through long term treatment. The combination therapies of simvastatin and antiplatlete drugs have more significant effects than antiplatlete therapy alone.
What problem does this paper attempt to address?